Hereditary transthyretin amyloidosis (HTA) Program in Pharmaceutical Benefits Scheme (PBS) 012-24070419
Expand allThis document outlines details of PBS-subsidised patisiran or vutrisiran for patients with hereditary transthyretin amyloidosis (HTA).
HTA and listing dates
HTA is a hereditary condition characterised by the buildup of abnormal deposits of a protein called amyloid (amyloidosis) in the body's organs and tissues.
Listing date:
- patisiran - 1 August 2024
- vutrisiran - 1 May 2025
See Written Authority Required Drugs for more details.
Enquiries
Transfer enquiries about prescription arrangements to PBS Complex Drugs Programs and choose the option relevant to the condition treated.
The Resources page contains:
- application forms
- contact details
- FAQs from Service Officers
- restriction and item codes
- the PBS schedule
- Services Australia website link
Related links
Online Pharmaceutical Benefits Scheme (PBS) Authorities System (OPA System)
Process telephone Authority approval application
Processing and National Demand Allocation (PaNDA)
Processing Complex Authority Required Listings
Processing Written Authority requests
Written Authority Required Drugs